Aminoglycoside Antibacterial [EPC]

44588 reported adverse events

Drugs of this class: TOBRAMYCIN TOBRAMYCIN AND DEXAMETHASONE LOTEPREDNOL ETABONATE AND TOBRAMYCIN BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE TOBRAMYCIN / DEXAMETHASONE TOBRAMYCIN INHALATION SOLUTION TOBRAMYCIN OPHTHALMIC SOLUTION AMIKACIN POLYMYXIN B SULFATE, BACITRACIN ZINC, NEOMYCIN SULFATE, PRAMOXINE HCL TOBRAMYCIN INHALATION TOBRAMYCIN SOLUTION

These side effects are most commonly reported by patients taking drugs of the Aminoglycoside Antibacterial [EPC] class:

# Side effect Count
0 OFF LABEL USE 4278
1 DYSPNOEA 3189
2 COUGH 3088
3 DEATH 2928
4 DRUG INEFFECTIVE 2908
5 HOSPITALISATION 2482
6 PNEUMONIA 2316
7 CONDITION AGGRAVATED 1717
8 INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS 1640
9 FATIGUE 1572
See all common reactions for Aminoglycoside Antibacterial [EPC]

Drugs of the Aminoglycoside Antibacterial [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS 1640 0.3010
1 CYSTIC FIBROSIS 1327 0.2394
2 MYCOBACTERIUM AVIUM COMPLEX INFECTION 420 0.1563
3 OTOTOXICITY 279 0.1507
4 SPUTUM INCREASED 325 0.1501
5 PULMONARY FUNCTION TEST DECREASED 470 0.1073
6 PSEUDOMONAS INFECTION 711 0.0828
7 BRONCHIECTASIS 346 0.0513
8 APHONIA 649 0.0465
9 PATHOGEN RESISTANCE 337 0.0369
See all enriched reactions for Aminoglycoside Antibacterial [EPC]